Other important side effects include:
Uric acid, lactate dehydrogenase, and alkaline phosphatase levels may rise and spontaneously return to normal levels. Heart attacks and abnormal heart rhythm.
GENERIC AVAILABLE: No
PREPARATIONS: Filgrastim is available as a liquid for injection in vials or pre-filled syringes containing 300 or 480 micrograms of drug.
STORAGE: Filgrastim should be stored at 2 C to 8 C (36 F to 46 F) and should not be frozen.
DOSING: The recommended dose is 5 to 10 mcg/kg per day. Filgrastim is administered intravenously or subcutaneously (under the skin) for 6 to 14 days. Filgrastim vials should not be shaken since the drug may be damaged, and bubbles may form that can prevent some of the drug from being drawn up into the syringe at the time of injection.
DRUG INTERACTIONS: No clinical studies have been done to determine if filgrastim interacts with other drugs.
PREGNANCY: There are no studies of filgrastim use in pregnant women. Women who become pregnant while receiving filgrastim should enroll in Amgen's Pregnancy Surveillance Program (1-800-772-6436).
NURSING MOTHERS: There are no studies to determine if filgrastim is excreted into breast milk.
Medically reviewed by Eni Williams, PharmD
Reference: FDA Prescribing Information
Quick GuidePancreatic Cancer Pictures Slideshow
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.